Tag: death

- The INDIGO study met its primary and all key secondary endpoints with statistically significant results -

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Sarepta To Contact Him Directly To Discuss Their Options

Bagsværd, Denmark, 15 August 2025 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved an additional indication for Wegovy^® (semaglutide 2.4 mg) based on a supplemental New Drug Application (sNDA) for treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis), in combination with a reduced calorie diet and increased physical activity.

SAN FRANCISCO, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Shares of Nutex Health Inc. (NASDAQ: NUTX) experienced a precipitous decline today, falling as much as 24% in intraday trading. The significant drop followed the company’s disclosure that it would not timely submit its financial results for the quarter ended June 30, 2025 - a development related to an ongoing investigation by law firm Hagens Berman into possible securities violations.

NEW YORK, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Sarepta Therapeutics, Inc. (“Sarepta” or “the Company”) (NASDAQ: SRPT) and certain of its officers.

Results support potential of efruxifermin (EFX) to reduce risk of fibrosis progression in patients with pre-cirrhotic (F2-F3) MASH

SALT LAKE CITY, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Security National Financial Corporation (SNFC) (NASDAQ symbol "SNFCA") announced financial results for the quarter ended June 30, 2025. For the three months ended June 30, 2025, SNFC’s after tax earnings decreased 10% from $7,271,000 in 2024 to $6,506,000 in 2025. For the six months ended June 30, 2025, after tax earnings decreased 26% to $10,845,000 from $14,746,000 in 2024.